Skip to main content
BioVaxys Technology Corp. logo

BioVaxys Technology Corp. — Investor Relations & Filings

Ticker · BIOV ISIN · CA09076M2004 LEI · 894500UD22QWRLZYJ229 CSE Professional, scientific and technical activities
Open in API
Filings indexed 436 across all filing types
Latest filing 2022-04-29 Board/Management Inform…
Country CA Canada
Listing CSE BIOV

About BioVaxys Technology Corp.

https://biovaxys.com/

BioVaxys Technology Corp. is a clinical-stage biopharmaceutical company specializing in the development and out-licensing of novel immunotherapy assets. The core technology is the proprietary DPX™ platform, a unique lipid-in-oil formulation designed for sustained, targeted immune responses. DPX forces active uptake into immune cells and lymph nodes, avoiding systemic side effects common to conventional delivery methods. The platform is versatile, supporting peptides, proteins, mRNA, and small molecules, and is being applied across oncology, infectious disease, allergy, and autoimmune disorders. The lead clinical asset, Maveropepimut-S (MVP-S), has demonstrated promising Phase 2B results in recurrent ovarian cancer and relapsed/refractory Diffuse Large B-Cell Lymphoma (DLBCL). The company is also integrating Artificial Intelligence to enhance immunotherapeutic discovery.

Recent filings

Filing Released Lang Actions
News release - English.pdf
Board/Management Information Classification · 100% confidence The document is a press release announcing the appointment of Mr. Anthony Dutton to the board of directors of BioVaxys Technology Corp. It contains biographical information about the new director and company background, but no financial data or report content. The document is clearly about a change in the company's board of directors, which fits the category of Board/Management Information (MANG). There is no indication that this is a full report, audit, or financial statement, nor is it a regulatory filing or announcement of a report publication. Therefore, the correct classification is MANG with high confidence.
2022-04-29 English
News release - English.pdf
Regulatory Filings Classification · 95% confidence The document is a press release announcing a supply agreement between BioVaxys Technology Corp. and Deaconess Research Institute for tumor cell supply related to the bioproduction of a vaccine candidate. It discusses the company's development plans, regulatory steps, and clinical trial intentions but does not contain any financial statements, earnings data, or detailed financial analysis. It is not a report, transcript, or regulatory filing but rather a corporate announcement about a business development and partnership. Therefore, it fits best under the category of a general regulatory announcement or miscellaneous corporate news, which corresponds to Regulatory Filings (RNS). The document length is about 9,482 characters, which is substantial but the content is clearly an announcement rather than a report or financial filing.
2022-04-25 English
52-109FV2 - Certification of interim filings - CFO (E).pdf
Regulatory Filings
2022-04-02 English
Interim MD&A - English.pdf
Regulatory Filings
2022-04-02 English
News release - English.pdf
Regulatory Filings Classification · 90% confidence The document is a press release announcing the expansion of BioVaxys Technology Corp.'s cancer vaccine platform and plans for clinical trials. It contains no financial statements, regulatory filings, or detailed financial performance data. It is not an earnings release, annual report, or interim report. It is a corporate announcement about product development and clinical trial plans, typical of a Capital/Financing Update or general corporate update. There is no indication of fundraising or capital structure changes, so Capital/Financing Update (CAP) is less fitting. It is not a regulatory filing or legal proceeding. The document is a corporate news announcement about product development and clinical trial plans, best classified as a Regulatory Filing (RNS) as a general corporate announcement that does not fit other categories.
2022-03-30 English
Notice of the meeting and record date - English.pdf
AGM Information Classification · 95% confidence The document is a notice regarding the upcoming Annual General Meeting (AGM) of BioVaxys Technology Corp., specifying the meeting date, record date, and other procedural details. It does not contain the AGM materials or presentations themselves, nor does it include financial data or voting results. The document is short (1098 characters) and serves as an announcement of the meeting and record date. Therefore, it fits the category of AGM Information (AGM-R), which covers presentations and materials shared during the AGM or related notices about the AGM.
2022-03-18 English

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.